Risk of lymphoma subtypes by family history of selected cancers in first degree relatives
| . | . | . | Family history of lymphoma subtype in first-degree relative* . | |||||
|---|---|---|---|---|---|---|---|---|
| Outcome . | Study Design . | References . | NHL . | HL . | CLL/Leukemia . | DLBCL . | FL . | LPL/WM . |
| NHL | Case-control | 12 | 1.8 (1.5-2.1) | 1.7 (1.2-2.3) | 1.5 (1.3-1.8) | — | — | — |
| Registry | 22 | 1.7 (1.4-2.2) | 1.4 (1.0-2.0) | 1.3 (0.9-1.9) | — | — | — | |
| CLL | Case-control | 12 | 1.9 (1.4-2.6) | 1.3 (0.6-2.6) | 2.4 (1.9-3.1) | — | — | — |
| Registry | 23 | 1.9 (1.5-2.3) | 1.5 (1.0-2.3) | 8.5 (6.1-12) | 1.0 (0.4-2.5) | 1.6 (0.9-2.8) | 4.0 (2.0-8.2) | |
| DLBCL | Case-control | 12 | 1.8 (1.5-2.3) | 2.1 (1.4-3.2) | 1.2 (0.9-1.5) | — | — | — |
| Registry | 24 | — | 2.4 (P < .05) | — | 9.8 (3.1-31) | No increase† | — | |
| FL | Case-control | 12 | 2.0 (1.6-2.5) | 1.5 (0.9-2.4) | 1.0 (0.7-1.3) | — | — | — |
| Registry | 24 | — | 1.4 (P > .05) | 1.8 (1.0-3.3) | No increase† | 4.0 (1.6-9.5) | — | |
| LPL/WM | Case-control | 12 | 1.2 (0.5-2.8) | 2.2 (0.5-9.4) | 2.2 (1.2-4.0) | — | — | — |
| Registry | 25 | 3.0 (2.0-4.4) | 0.8 (0.3-2.2) | 3.4 (1.7-6.6) | — | — | 20 (4.1-98) | |
| MZL | Case-control | 12 | 1.7 (1.1-2.5) | 2.7 (1.4-5.5) | 1.7 (1.2-2.4) | — | — | — |
| MCL | Case-control | 12 | 2.0 (1.1-3.3) | 1.5 (0.5-5.0) | 2.0 (1.2-3.2) | — | — | — |
| PTCL | Case-control | 12 | 1.7 (0.9-3.1) | 0.9 (0.1-4.4) | 1.8 (1.1-3.1) | — | — | — |
| Registry | 24 | — | No increase† | No increase† | No increase† | No increase† | — | |
| HL | Case-control | 26 | 3.3 (1.3-8.0) | 3.3 (0.5-22) | 6.3 (1.3-30) | — | — | — |
| Registry | 24,27 | 1.3 (0.9-1.8) | 3.1 (1.8-5.3) | 2.1 (1.2-3.8) | 2.0 (1.1-4.0) | 1.4 (P > .05) | — | |
| . | . | . | Family history of lymphoma subtype in first-degree relative* . | |||||
|---|---|---|---|---|---|---|---|---|
| Outcome . | Study Design . | References . | NHL . | HL . | CLL/Leukemia . | DLBCL . | FL . | LPL/WM . |
| NHL | Case-control | 12 | 1.8 (1.5-2.1) | 1.7 (1.2-2.3) | 1.5 (1.3-1.8) | — | — | — |
| Registry | 22 | 1.7 (1.4-2.2) | 1.4 (1.0-2.0) | 1.3 (0.9-1.9) | — | — | — | |
| CLL | Case-control | 12 | 1.9 (1.4-2.6) | 1.3 (0.6-2.6) | 2.4 (1.9-3.1) | — | — | — |
| Registry | 23 | 1.9 (1.5-2.3) | 1.5 (1.0-2.3) | 8.5 (6.1-12) | 1.0 (0.4-2.5) | 1.6 (0.9-2.8) | 4.0 (2.0-8.2) | |
| DLBCL | Case-control | 12 | 1.8 (1.5-2.3) | 2.1 (1.4-3.2) | 1.2 (0.9-1.5) | — | — | — |
| Registry | 24 | — | 2.4 (P < .05) | — | 9.8 (3.1-31) | No increase† | — | |
| FL | Case-control | 12 | 2.0 (1.6-2.5) | 1.5 (0.9-2.4) | 1.0 (0.7-1.3) | — | — | — |
| Registry | 24 | — | 1.4 (P > .05) | 1.8 (1.0-3.3) | No increase† | 4.0 (1.6-9.5) | — | |
| LPL/WM | Case-control | 12 | 1.2 (0.5-2.8) | 2.2 (0.5-9.4) | 2.2 (1.2-4.0) | — | — | — |
| Registry | 25 | 3.0 (2.0-4.4) | 0.8 (0.3-2.2) | 3.4 (1.7-6.6) | — | — | 20 (4.1-98) | |
| MZL | Case-control | 12 | 1.7 (1.1-2.5) | 2.7 (1.4-5.5) | 1.7 (1.2-2.4) | — | — | — |
| MCL | Case-control | 12 | 2.0 (1.1-3.3) | 1.5 (0.5-5.0) | 2.0 (1.2-3.2) | — | — | — |
| PTCL | Case-control | 12 | 1.7 (0.9-3.1) | 0.9 (0.1-4.4) | 1.8 (1.1-3.1) | — | — | — |
| Registry | 24 | — | No increase† | No increase† | No increase† | No increase† | — | |
| HL | Case-control | 26 | 3.3 (1.3-8.0) | 3.3 (0.5-22) | 6.3 (1.3-30) | — | — | — |
| Registry | 24,27 | 1.3 (0.9-1.8) | 3.1 (1.8-5.3) | 2.1 (1.2-3.8) | 2.0 (1.1-4.0) | 1.4 (P > .05) | — | |
DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; LPL, lymphoplasmacytic lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; PTCL, peripheral T-cell lymphoma; WM, Waldenstrom macroglobulinemia.
ORs (for case-control design) or RR (for registry design) and 95% CI.
Estimate not reported.